The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) is a huge mover today! The stock increased 4.12% or $0.18 on October 3, hitting $4.55. About 95,602 shares traded hands. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has declined 2.89% since February 29, 2016 and is downtrending. It has underperformed by 15.10% the S&P500.
The move comes after 5 months positive chart setup for the $66.60M company. It was reported on Oct, 4 by Barchart.com. We have $9.83 PT which if reached, will make NASDAQ:SNSS worth $77.26M more.
Analysts await Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to report earnings on November, 3. They expect $-0.12 earnings per share, down 33.33% or $0.03 from last year’s $-0.09 per share. After $-0.12 actual earnings per share reported by Sunesis Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Ratings Coverage
Out of 4 analysts covering Sunesis Pharmaceuticals (NASDAQ:SNSS), 1 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 25% are positive. Sunesis Pharmaceuticals has been the topic of 4 analyst reports since July 24, 2015 according to StockzIntelligence Inc. TH Capital downgraded Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) on Friday, July 24 to “Sell” rating. The stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has “Outperform” rating given on Friday, July 29 by Wells Fargo. The rating was downgraded by Cowen & Co to “Market Perform” on Friday, July 24. Cantor Fitzgerald downgraded the shares of SNSS in a report on Friday, July 24 to “Hold” rating.
According to Zacks Investment Research, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.”
Another recent and important Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) news was published by Globenewswire.com which published an article titled: “Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results …” on September 01, 2016.
SNSS Company Profile
Sunesis Pharmaceuticals, Inc., incorporated on February 10, 1998, is a biopharmaceutical company. The Firm focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Firm offers QINPREZOTM (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.